Opinion

Video

Future Perspectives in Large B-Cell Lymphoma

Author(s):

Frederick Locke, MD

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
Related Content
MDS/CMML | Corona Borealis – stock.adobe.com
February 7th 2025

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
February 3rd 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.
February 1st 2025

The OncFive: Top Oncology Articles for the Week of 1/26

FDA
January 30th 2025

MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma